315 related articles for article (PubMed ID: 23576620)
1. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.
Roe CM; Fagan AM; Grant EA; Hassenstab J; Moulder KL; Maue Dreyfus D; Sutphen CL; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
Neurology; 2013 May; 80(19):1784-91. PubMed ID: 23576620
[TBL] [Abstract][Full Text] [Related]
2. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.
Palmqvist S; Hertze J; Minthon L; Wattmo C; Zetterberg H; Blennow K; Londos E; Hansson O
PLoS One; 2012; 7(6):e38639. PubMed ID: 22761691
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
Roe CM; Fagan AM; Grant EA; Marcus DS; Benzinger TL; Mintun MA; Holtzman DM; Morris JC
Arch Neurol; 2011 Sep; 68(9):1145-51. PubMed ID: 21911695
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
9. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.
Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS;
Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682
[TBL] [Abstract][Full Text] [Related]
11. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A
Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
[TBL] [Abstract][Full Text] [Related]
16. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
[TBL] [Abstract][Full Text] [Related]
18. Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
Babulal GM; Chen L; Murphy SA; Carr DB; Morris JC
Neurology; 2024 Jun; 102(12):e209426. PubMed ID: 38776513
[TBL] [Abstract][Full Text] [Related]
19. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
20. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
